



Myelodysplastic syndromes (MDS) are a heterogeneous group of 
clonal stem cell disorders, characterized by ineffective hematopoiesis, 
a variable degree of cytopenia, and an increased risk for developing 
acute myelogenous leukemia (AML) [1]. MDS with ≥ 2% blasts in PB 
or ≥ 5% but less than 20% blasts in the BM is classified as MDS- 
EB in the most recent WHO classification of myeloid neoplasms [2]. 
The variant MDS-EB in transformation (MDS-EB-t) is retained in the 
pediatric classification of MDS, [3] and is characterized by a PB or 
BM blast percentage between 20% and 29%. However, it must be 
emphasized that the blast percentage in a single specimen is in itself 
not sufficient for differentiating MDS-EB or MDS-EB-t from AML. MDS 
is rare in children, presents with advanced disease (MDS-EB and 
MDS-EB-t) and progress to leukemia more often than adults [4, 5]. 
Accounting for 4% of all pediatric hematopoietic neoplasia, MDSs 
are far less common in children than in adults [6]. Majority of the 
pediatric patients have associated chromosomal abnormalities at 
presentation, with monosomy 7 being the most frequent [7]. MDS 
classification that includes some of the FAB subtypes (Juvenile 
Myelomonocytic Leukemia syndrome and others) has not been 
universally accepted and today there is a consensus that these 
disorders are distinct from MDS [8]. An international consensus has 
been recently achieved on the classification of MDS in childhood. 
This classification includes refractory cytopenia (RC) and refractory 
anemia with excess blasts (MDS-EB) [9]. Therapy-related MDS are 
generally considered separately when given the different etiology, 
clinical characteristics, and poorer prognosis [10, 11]. There are a 
number of differences between adult and pediatric manifestation of 
MDS. In children, refractory anemia (RA) with ringed sideroblasts 
and MDS associated with del(5q) chromosome are exceedingly 
rare. In addition, the importance of multilineage dysplasia in RA is 
unknown. Anemia is generally the main presenting symptom in adults 
with RA, but in childhood cases, neutropenia and thrombocytopenia 
are frequently observed. Therefore, “refractory cytopenia” was felt 
to be a more suitable term for pediatric MDS without excess blasts. 
Furthermore, in children, there are no data to indicate whether a blast 
threshold of 20% is better than the traditional 30% to distinguish MDS 
from de novo AML. To accommodate these characteristics of pediatric 
MDS, a simple classification scheme based on morphological 
features and conforming to the WHO suggestions were proposed [1]. 
It recognizes three diagnostic groups: RC (BM blasts < 5%), RA with 
excess blasts (RAEB) (BM blasts 5%–20%) and RAEB-T (BM blasts 
20%–30%). Allogeneic Hematopoietic Cell Transplantation (HCT) 
is the treatment of choice for the majority of young patients with 
MDS or myelodysplastic syndrome-related AML who have a histo- 
compatible sibling. Disease-free survival ranges from 29% to 40% 
with a corresponding non-relapse mortality of 37% to 50% and a rate 
of relapse ranging from 23% to 48%, if the donor is an HLA-identical 
sibling in patients with advanced disease. If unrelated donors were 
used, after standard myeloablative conditioning, the treatment-related 
mortality will exceed 50% [6]. Despite an improvement in the results 
of allogeneic HCT during the past decade mainly due to a lower 
treatment-related mortality, there still is a high morbidity, which makes 
allogeneic stem cell transplantation after standard conditioning only 
appropriate for younger patients [12]. Graft failure and relapse of the 
primary disease were the main causes of treatment failure. However, 
methods to further improve outcome in patients with MDS undergoing 
allogeneic HCT are needed to decrease the relapse rate. This could 
be achieved through serial post HCT analysis of chimerism data to 
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detect the development of mixed chimerism, which is a predictor of 
poor outcome, and the use of preemptive immunotherapy with donor 
lymphocyte infusions or discontinuation of the immunosuppressive 
therapy. A previous study reporting the results of HCT in MDS from 
the region has highlighted better outcome in younger patients [13]. 
We conducted a retrospective observational study to review the 
outcome of HCT in pediatric patients with MDS treated at King Faisal 
Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Patients and methods
A group of 35 transplant naïve pediatric patients (age ≤ 14 years at 
diagnosis) with MDS who underwent HCT at our institution from Jan
1993 to December 2016 were identified. A total of 37 patients were 
transplanted in allogeneic fashion from Jan 1993 to December 2016 
at our institution. Two (2) were excluded for having previously been 
transplanted at other hospitals. Data on demographics, diagnosis, 
transplant-related parameters and outcome were extracted from 
prospectively maintained clinical databases and through medical 
charts review. After quality assurance checks, the dataset was then 
transferred to IBM-SPSS for Windows Version 20.0 for final analyses. 
Based on WHO Criteria, 26 (74.3%) patients were categorized as 
Low Risk (LR) and remaining nine (25.7%) as High Risk (HR) MDS. 
Patients’ characteristics and HCT related parameters are presented 
in table I. All patients received cyclosporine (CsA) or methotrexate 
(MTX) based graft versus host disease (GvHD) prophylaxis and were 
conditioned with myeloablative regimen. Conditioning regimens, 
GvHD prophylaxis, diagnosis and staging of GvHD were based 
on Center for International Blood and Marrow Transplant Research 
(CIBMTR) guidelines.
Table I. Patient characteristics, transplant and outcome related parameters





9 (25.7) Total n = 35
Gender
Female 10 (38.5) 3 (33.3) 13 (37.1)
Male 16 (61.5) 6 (66.7) 22 (62.9)
Age at HCT (years from diagnosis)
< 5 years 16 (61.5) 5 (55.6) 21 (60)
5–10 years 8 (30.8) 3 (33.3) 11 (31.4)
10 and above 2 (7.7) 1 (11.1) 3 (8.6)
Median (Min-Max) 3.3 (0.8-14.8) 5.0 (3.1-13.6) 4.0 (0.8-14)








Monosomy 7 (+) 8 (33.3) 3 (33.3) 11 (33.3)
Source of Stem Cells
Bone Marrow 23 (88.5) 8 (88.9) 31 (88.6)
Cord Blood 3 (11.5) 1 (11.1) 4 (11.4)













HLA-Identical Siblings 20 (76.9) 8 (88.9) 28 (80)
HLA-Identical Other Relatives 2 (7.7) - 2 (5.7)
Related 1-Ag Mismatch 1 (3.8) - 1 (2.9)
Un-Related 1-AG Mismatch 1 (3.8) 1 (11.1) 2 (5.7)
Un-Related 2-AG Mismatch 2 (7.7) - 2 (5.7)
Conditioning regimen
Bu/Cy 9 (34.6) 1 (11.1) 10 (28.6)
Bu/Cy/ATG 7 (26.9) - 7 (20)
Bu/Cy/VP-16 10 (38.5) 8 (88.9) 18 (51.4)
Donor Gender
Male 17 (65.4) 7 (77.8) 24 (68.6)
Female 9 (34.6) 2 (22.2) 11 (31.4)
Outcome parameters
Relapse of the primary disease 3 (11.5) 3 (33.3) 6 (17.1)
Death 8 (30.8) 4 (44.4) 12 (34.4)
Alive – in remission 18 (69.2) 5 (55.6) 23 (65.7)




All continuous data are presented as median with minimum and 
maximum points. For categorical variables, chi-square test for 
independence was used to test for the independence of association. 
Kaplan-Meier curves were drawn for survival analysis and tested for 
any difference between the survival times using the Tarone-Ware test 
in uni-variate setting. For EFS, primary or secondary graft failure, 
relapse or death, whichever came first, were considered as event. 
Cox regression analysis on overall survival data was carried 
out in multivariable environment to test for the significance of various 
variables in terms of their role towards survival time.
Results
With a median follow-up time of 112.4±31.7 months, the cumulative 
probability of five-year overall survival (OS) was 64.5%±8.3% for the 
whole cohort, 67.1%±9.7% for LR and 55.6%±16.6% for HR MDS 
patients respectively (p-value: 0.530, Fig. 1). The probability of five- 
year overall survival same was 72.7%±13.4% in the sub-group of 
patients with age at transplant between 5-10 years as compared to 
66.7%±27.2% in those with over 10 years followed by 60.5%±10.9% 
who were transplanted in the first five years of their life. However, this 
difference did not achieve statistical significance (table II). Event Free 
survival (EFS) for our patients in this study was 64.5%±8.3%.
Relapse of primary disease was observed in 17.1% (6 of 35; 3 in 
each of the risk groups). Mortality Rate was significantly lower in non- 
relapse group 20.7% (6 of 29) compared to the relapsed patients 
(100%, n = 6; p-value: 0.001) as expected. Five patients who relapsed 
(83.3%) had received Bu/Cy/VP-16 as conditioning while only one 
patient (16.7%) from the Bu/Cy/±ATG (ATG-F 10 mg/kg/day x 4 
days) conditioning group experienced relapse of the primary disease 
(p-Value: 0.177).
Based on chimerism studies, 93.9% (31) of evaluable patients (alive) 
have been engrafted, while among the remaining, one was never 
engrafted and the other patient, was engrafted and then had a failed 
graft.
Based on chimerism studies, all those patients alive at Day-100 
(n = 29) were fully engrafted; 21 (72.4%) were from LR and eight 
(27.6%) from HR MDS. Among those at risk (n = 29) beyond 
Day-100, three patients expired from each risk group as engrafted, 
thus making our mortality count of twelve at the time of this review. 
Cumulative incidence of acute graft versus host disease (aGvHD) 
was 37.1% (13); ten patients (38.5%) were from LR and three (33.3%) 
from HR (p-value: 0.749). Overall Grade I aGvHD was seen in seven 
(53.8%) while Grade II was recorded in six patients (46.2%). No 
severe Grade III or above aGvHD was observed. There were nine (9) 
instances of skin a GvHD while seven (7) instances of the same 
were seen for the gut. No hepatic a GvHD was observed in our group 
of patients.
The incidence of chronic graft versus host disease (cGvHD) was 
21.2% (seven in thirty-three cases at risk; six from LR and one from 
HR MDS); four (57.1%) had extensive while for the remaining three 
(42.9%), cGVHD was observed to be limited in grade.
Hemorrhagic cystitis during the same period was seen in five (14.3%) 
patients (all LR MDS). Veno-occlusive disease (VOD) was seen in two 
patients (5.7%, all LR MDS) and interstitial pneumonia in one (2.9%, 
LR MDS) case.
Transplant related mortality (TRM) was 17.1% (6); five (19.2%) 
patients from LR and one (11.1%) from HR MDS group succumbed 
within first 100 days of infusion. Of these six patients, two expired 
engrafted, one had a primary graft failure and the other one 
post-secondary graft failure (HR MDS) due to progressive disease. 
Majority of our patients (28, 80%) had a matched sibling as the donor. 
When analyzed for survival outcome in this sub-group by conditioning 
regimens (Bu/Cy/±ATG, n = 13 vs. Bu/Cy/VP-16, n = 15), cumulative 
probability of five year OS and EFS were better in the former sub-
group of patients than the later (83.9±10.4 vs. 53.3±12.9 and 
83.9±10.4 vs. 53.3±12.9; p-values: 0.087 and 0.073 respectively). 
However, the difference did not reach statistical significance. None 
of the patients who received Bu/Cy/±ATG conditioning experienced 
relapse of the primary disease compared to those who got Bu/Cy/ 
VP-16 (5 cases, 33%, p-value: 0.044), in the same sub-group, where 
the donor was a matched sibling.
Relapse of the primary disease was higher in patients with matched 
sibling donors (5 out of 28, 17.9%) when compared to their 
counterparts (1 out of 7, 14.3%, p-value: 1.0). The same was lower in 
LR (3 out of 26, 11.5%) than in HR MDS (3 out of 9, 33.3%, P-Value: 
0.162; table I). Both OS and EFS, exhibited better trend in patients for 
a matched sibling donor (table II). With a median follow-up of 112.4 
months and 12 events of mortality (2 within D-100), 3-year overall 
and event-free survival of our cohort of patients was 0.681±0.080. 
In terms of conditioning regimen, non-relapse mortality (n = 5) in LR 
MDS group was 20% (3 out of 15) in Bu/Cy/±ATG and 25% (2 out of 
8) in Bu/Cy/VP-16 regimens respectively (p-value: 1.0). Six patients 
from those with stable disease at HCT (21.4%) experienced post- 
HCT relapse of the primary disease compared to none who were 
in remission (p-value: 0.311). No significant association between 
the relapse of primary disease and donor HLA-type, age at and 
Fig. 1. Overall survival with respect to Risk Groups
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time to transplantation, donor and recipient gender and incidence of 
a  GvHD was found in this study. Among thirty-three patients tested 
for monosomy 7, eleven (33.3%) were found to be positive. Of these, 
two patients relapsed (18.2%); one from each risk group and both had 
a matched sibling donor.
In uni-variate analysis, time to transplant from diagnosis (> 6 months), 
pre-transplant disease status (In remission vs. Stable disease), donor 
and recipient gender, monosomy 7 positivity, conditioning regimen 
(Bu/Cy/±ATG vs. Bu/Cy/VP-16), the source of Stem Cells (Bone 
marrow vs. Cord blood), or occurrence of aGvHD had no significant 
impact on EFS and OS time (table II). In multi-variable setting, 
when adjusted for risk stratification or donor HLA-type, conditioning 
regimen did not turn out to be of any statistical significance for overall 
survival (OS).
No secondary malignancy was recorded in our cohort of patients 
while on follow-up. At the last update, all surviving patients were 
maintaining sustained donor chimerism.
Discussion
Allogeneic HCT currently offers the best chance of cure and long- 
term survival for children with advanced MDS [14, 15]. In this 
article, we reported the outcome of pediatric patients with MDS 
treated with allogeneic HCT at a single institution. To study a more 
homogeneous cohort of patients, and in compliance with the recent 
WHO classification, we excluded patients with secondary MDS 
(treatment related MDS, and MDS secondary to inborn bone marrow 
failure syndromes) from this analysis. Myeloablative regimen was 
used for all of our patients, while for 51.4% it was Bu/Cy /VP-16. The 
safety profile of etoposide as part of the conditioning regimen has 
been widely explored in adult studies [16]. In children, however, few 
studies have addressed the use of high-dose etoposide (40-60 mg/kg) 
in combination with other agents in the preparative regimens with 
a lower dose of Bu/Cy. In our study, VP-16 was well tolerated and 
had less toxicity with no increased incidence of GvHD or VOD. This 
Table II. Cumulative probability of five year survival with respect to factors of interest
Event Free Survival P-Value Overall Survival P-Value
Age at HCT 0.986 0.990
< 5 years 60.5±10.9 60.5±10.9
5–10 years 72.7±13.4 72.7±13.4
≥ 10 years 66.7±27.2 66.7±27.2
Recipient gender 0.790 0.724
Female 67.3±13.6 67.3±13.6
Male 62.5±10.6 62.5±10.6
Monosomy 7 (n = 11) 0.682 0.730
Negative 60.9±11.1 60.9±11.1
Positive 72.7±13.4 72.7±13.4
Time to HCT from diagnosis 0.979 0.952
≤ 6 months 63.5±13.1 63.5±13.1
> 6 months 64.6±11.0 64.6±11.0
Pre-HCT disease status 0.871 0.927
In remission 71.4±17.1 71.4±17.1
Not in Remission 63.6±9.2 63.6±9.2
Conditioning regimen 0.200 0.243
Bu/Cy/±ATG 74.7±11.0 74.7±11.0
Bu/Cy/VP-16 55.0±11.9 55.0±11.9
Cell Source 0.547 0.478
Bone marrow 66.7±8.7 66.7±8.7




Donor gender 0.427 0.447
Female 50.9±16.3 50.9±16.3
Male 70.3±9.4 70.3±9.4
Donor HLA type 0.820 0.763




finding is comparable with previous study from the same center by 
Al-Seraihy et al [13]. Late complication of etoposide like secondary 
malignancy especially AML was not noted in our study. Three-year OS 
and EFS of our cohort of patients was 0.681±0.080. The probability 
of five-year overall survival was 0.727±0.134 in the sub-group of 
patients with age at transplant between 5-10 years as compared to 
0.667±0.272 in those with over 10 years followed by 0.605±0.109 who 
were transplanted in first five years of their life. Historically, HCT with 
a myeloablative regimen has been reported with an EFS of 75% with 
TRM being the major cause of treatment failure [17]. In terms of OS 
and EFS, our results compare favorably with those reported recently 
by European Working Group of Myelodysplastic Syndromes (MDS) 
in Childhood (EWOG–MDS) reported the experience with overall, 64 
patients are alive after HSCT, an estimate of survival of 63% (53–73) 
at 5 years with a median observation time of 5.2 years (1.0–10.9), 
59 patients are alive in the first complete remission after HSCT. The 
5-year probability of EFS after the first allograft is 59% (49–69) [6]. 
In view of these findings, reduced-intensity conditioning might be 
an attractive approach at least for patients with hypocellular marrow 
and normal karyotype [18, 19]. In a pilot study conducted in nineteen 
children treated at centers affiliated with EWOG-MDS, HCT after a 
preparative regimen that includes thiotepa and fludarabine resulted 
in a probability of OS of 84% and an EFS reaching 74% [19]. These 
results have considerably improved over time, since the last update 
of the EWOG-MDS reported an OS of 94% and an EFS approaching 
88% in 169 patients with RCC [20]. One of the most controversial 
issues in the treatment of children with advanced MDS is the impact 
of intensive chemotherapy before HCT. Children with MDS treated 
on AML protocols have been reported to experience a high rate of 
induction failure and relapse, resulting in OS of approximately 30% [21-
24]. Likewise, patients receiving allogeneic HCT as primary treatment 
have a considerable risk of relapse, as well as transplantation-related 
toxicity [21, 25, 26]. Therefore, the role of intensive chemotherapy 
before HCT for patients with advanced MDS has remained a matter 
of debate. In this Study, the use of pre-transplant chemotherapy pre-
transplant did not seem to improve the EFS or the outcome, although, 
the small sample size of our study and only 2 patients received chemo 
may be enabled to conduct comparative analysis. We were unable to 
do any comparative analysis in this regard as only two patients were 
treated with pre- transplant chemotherapy in our cohort.
Relapse has been a major contributor to mortality in pediatric patients, 
with a statistically significant higher relapse rate in MDS- EB and 
MDS-EB-t cases as compared to RC. In this regard, report from Al-
Seraihy et al showed no correlation between relapse rate and MDS 
classification, which was comparable to other studies [13]. In addition 
to graft failure, infections secondary to immunosuppression from 
GvHD and its therapy were a major cause of non-relapse mortality 
in our patients, as shown in other series [25, 26, 27]. Cumulative 
incidence of acute GVHD was 37.1%, overall grade I a GVHD was 
seen in 53.8% while grade II was recorded in 46.2%. No severe grade 
III or above a GVHD was observed. The incidence of chronic GVHD 
was 21.2% in 33. 57.1% had extensive while the remaining in 42.9% 
it was limited. No severe acute GvHD was seen in our patients, this is 
due to utilization of intensive GvHD prophylaxis. Additionally, chronic 
GVHD was observed in a patient with a female adult donor, or among 
those with antigen mismatched donor HLA.
Donor type has always been considered as a major factor influencing 
the outcome following allogeneic HCT. Studies specifically addressing 
the role of HCT in children with MDS have indicated a probability of an 
EFS of about 50% following transplant with an HLA- matched family 
donor [25, 26], the same as obtained similar to what was observed 
in our series. The use of unrelated BM donors was associated with 
a higher incidence of acute and chronic GvHD, a higher transplant 
related mortality, and EFS probability of around 29% [28, 29]. 
Parikh et al [24] reported encouraging data regarding the use of UCB 
as a stem cell source for children with primary and secondary MDS 
achieving a three-year EFS of 60.9%, with a lower incidence of acute 
and chronic GVHD.
Conclusion
Although etoposide based conditioning was observed to be well 
tolerated yet, the Bu/Cy/±ATG conditioning regimen showed a trend of 
superiority for OS and EFS in our small series of patients undergoing 
HCT for MDS. The relapse incidence in our cohort was 11.5% in LR 
MDS group.
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